Of Interest

In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential for side effects, which can be severe and occur in more than half of all patients.

Skin cancer in people of color is often diagnosed at advanced stages, resulting in higher morbidity and mortality rates.

The investigational new drug application for LP-184 has been cleared by the FDA.

Ocular oncologists discover new diagnostic tool that may lead to better outcomes for patients with eye cancer.